- Home
- ZBAI vs RLYB Comparison
ZBAI vs RLYB Comparison
Compare ZBAI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- RLYB
- Stock Information
- Founded
- ZBAI 2015
- RLYB 2018
- Country
- ZBAI United States
- RLYB United States
- Employees
- ZBAI N/A
- RLYB N/A
- Industry
- ZBAI Professional Services
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAI Consumer Discretionary
- RLYB Health Care
- Exchange
- ZBAI Nasdaq
- RLYB Nasdaq
- Market Cap
- ZBAI 17.3M
- RLYB 14.4M
- IPO Year
- ZBAI N/A
- RLYB 2021
- Fundamental
- Price
- ZBAI $0.49
- RLYB $0.40
- Analyst Decision
- ZBAI
- RLYB Hold
- Analyst Count
- ZBAI 0
- RLYB 3
- Target Price
- ZBAI N/A
- RLYB $15.00
- AVG Volume (30 Days)
- ZBAI 962.4K
- RLYB 240.7K
- Earning Date
- ZBAI 03-13-2025
- RLYB 05-08-2025
- Dividend Yield
- ZBAI N/A
- RLYB N/A
- EPS Growth
- ZBAI N/A
- RLYB N/A
- EPS
- ZBAI N/A
- RLYB N/A
- Revenue
- ZBAI $670,000.00
- RLYB $848,000.00
- Revenue This Year
- ZBAI N/A
- RLYB N/A
- Revenue Next Year
- ZBAI N/A
- RLYB N/A
- P/E Ratio
- ZBAI N/A
- RLYB N/A
- Revenue Growth
- ZBAI 67.50
- RLYB N/A
- 52 Week Low
- ZBAI $0.47
- RLYB $0.22
- 52 Week High
- ZBAI $2.50
- RLYB $1.73
- Technical
- Relative Strength Index (RSI)
- ZBAI N/A
- RLYB 59.92
- Support Level
- ZBAI N/A
- RLYB $0.27
- Resistance Level
- ZBAI N/A
- RLYB $0.49
- Average True Range (ATR)
- ZBAI 0.00
- RLYB 0.06
- MACD
- ZBAI 0.00
- RLYB 0.01
- Stochastic Oscillator
- ZBAI 0.00
- RLYB 57.34
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.